Kieran Gallahue - 08 Feb 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Director
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
08 Feb 2022
Net transactions value
-$2,854,630
Form type
4
Filing time
08 Feb 2022, 19:19:26 UTC
Previous filing
15 Jun 2021
Next filing
11 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $718,880 +32,256 +940% $22.29 35,689 08 Feb 2022 Direct
transaction EW Common Stock Sale $3,573,510 -32,256 -90% $110.79 3,433 08 Feb 2022 Direct F1
holding EW Common Stock 56,751 08 Feb 2022 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Director Stock Option (Right to Acquire) Options Exercise $0 -32,256 -100% $0.000000* 0 08 Feb 2022 Common Stock 32,256 $22.29 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $110.50 to $111.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

On May 29, 2020, the common stock of the Issuer split 3-for-1, resulting in the Reporting Person's ownership of additional shares of common stock and stock options. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.